784156-56-5

Upstream product

• 784156-57-6 di-tert-butyl [(3R,6S)-6-(2,3-difluorophenyl)-1-(2-hydroxy-2-methylpropyl)-2-oxoazepan-3-yl]imidodicarbonate 
• 34404-30-3 N-(tert-butoxycarbonyl)-D-glutamic acid 1-benzyl ester 
• 880144-45-6 benzyl (5S)-N,N-bis(tert-butoxycarbonyl)-5-(2,3-difluorophenyl)-6-nitro-D-norleucinate 
• 784156-34-9 (R)-benzyl 2-[bis(tert-butoxycarbonyl)amino]-5-oxopentanoate 
• 784156-32-7 1-benzyl 5-methyl N,N-bis(tert-butoxycarbonyl)-D-glutamate 
• 784156-96-3 (5S)-N₂,N₂-bis(tert-butoxycarbonyl)-5-(2,3-difluorophenyl)-D-lysine 
• 784156-33-8 benzyl (2R,5E)-2-[bis(tert-butoxycarbonyl)amino]-6-nitrohex-5-enoate 

Relevant academic research and scientific papers

CARBOXAMIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: I wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as mi

CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.